Using MRI to Differentiate Between Brain Tumors and Radiation Effects
Official title: Development of Magnetic Resonance Fingerprinting for Characterization of Brain Tumors After Radiotherapy
Run by Case Comprehensive Cancer Center · NCT06101069 · Data updated 2026-11-12
This study is testing a new MRI technique to see if it can help tell the difference between brain tumors and radiation damage in people who have had radiation therapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Case Comprehensive Cancer Center Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (Cleveland, Ohio and 1 other locations) |
| Status | Recruiting |
| Started | October 14, 2024 |
| Main results expected | January 2027 |
| Study ends | September 2027 |
| Registry record updated | October 20, 2026 |
| Trial ID | NCT06101069 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with a history of brain tumors or radiation therapy, as well as healthy individuals without brain diseases.
✕Probably not a fit
Patients with acute neurological conditions or those who are unable to undergo MRI due to contraindications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study explores the use of Magnetic Resonance Fingerprinting (MRF) combined with intravoxel incoherent motion (IVIM) MRI to create high-quality images of the brain in just 5 minutes. The goal is to differentiate between brain tumors and radiation necrosis in patients who have undergone radiation therapy. Participants will include individuals with a history of brain tumors or radiation treatment, as well as healthy controls. The study aims to provide a non-invasive imaging solution that could replace the need for invasive biopsies.
Why it matters
Potential benefit: If successful, this approach could significantly improve the accuracy of brain tumor diagnosis and treatment planning, reducing the need for invasive procedures.
How similar studies have gone: Other studies utilizing advanced MRI techniques have shown promise in improving diagnostic accuracy, suggesting potential success for this novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria for Healthy Participants: * Ages 18 - 60 * No history of cerebrovascular disease * No cognitive impairments * Able to provide informed consent Inclusion Criteria for Participants with Brain Tumors: * Biopsy-proven cases of developed recurrent tumor or radiation necrosis, OR * a. PET identified with developed recurrent tumor or radiation necrosis. OR * b. Highly suspicious case with developed recurrent tumor or radiation necrosis confirmed by tumor board, attending physician or surgeon. * Age: 18 years and over * ECOG performance status 0-2. * Life expectancy \> 6 months. * Participant with other sites of extracranial metastatic disease or any prior or current systemic therapies will be considered and evaluated by the investigators of the study on a subject basis. Inclusion Criteria for Participants with Brain Metastases or Primary Gliomas: * Radiology identified with developed primary gliomas tumor or brain metastases, OR * a. PET identified with developed gliomas tumor or brain metastases, OR * b. Highly suspicious case with developed gliomas tumor or brain metastases confirmed by tumor board * Participants must not have received prior radiation or surgical treatment for brain metastases or primary glioma. * Age: 18 years and over * ECOG performance status 0-2 * Life expectancy \> 6 months. * Participant with other sites of extracranial metastatic disease or any prior or current systemic therapies will be considered and evaluated by the investigators of the study on a subject basis. Inclusion Criteria for Participants with Meningiomas: * Radiology identified with resectable meningioma * Participants have no prior radiation or surgical treatment for brain lesions * Age: 18 years or older * ECOG performance status 0-2 * Life expectancy \> 6 months. * Participants with other sites of extracranial metastatic disease or any prior or current systemic therapies will be considered and evaluated by the investigators of the study on a subject basis. Exclusion Criteria: * Pregnant women OR lactating women * Participants with ferromagnetic or otherwise non-MRI compatible aneurysm clips. * Participants who cannot go into the MRI scanner due to metal implants and other medical conditions. * The presence of an implanted medical device that is not MRI-compatible, including, but not limited to: pacemaker, defibrillator. * Participants with contraindications for MRI due to embedded foreign metallic objects such as bullets, shrapnel, metalwork fragments, or other metallic material. * Known history of severe claustrophobia. * Participants under the age of 18 * Participants unable to lay still in the scanner for 30 minutes at a time.
Where it's running
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States Recruiting -
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States Recruiting
Study contacts
- Principal investigator: Lan Lu, PhD — Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
- Study coordinator: Lan Lu, PhD
- Email: TaussigResearch@ccf.org
- Phone: 1-866-223 8100
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combining TIL Therapy and Pembrolizumab for Advanced Brain Cancer
This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with Pembrolizumab to see if it helps people with advanced brain cancer feel better and live longer.
-
Evaluating Bevacizumab with Focused Ultrasound for Recurrent Glioblastoma
This study is testing if adding focused ultrasound to the standard treatment of Bevacizumab can help people with recurrent glioblastoma feel better and live longer.
-
Detecting microplastics in patients undergoing neurosurgery
This study is trying to see if tiny pieces of plastic are found in the blood, brain fluid, and brain tissue of patients who are having brain surgery.
-
HOPE: Clinical, Pathology, and Imaging Project for Brain Tumors
This project collects clinical records, MRI scans, and pathology data from people with glioma and other primary brain tumors to build large databases for improving diagnosis and care.
-
Impact of Radiotherapy on Neurocognition in Brain Tumor Patients
This study is testing how radiotherapy affects thinking and memory in adults with brain tumors over time to see if certain treatments lead to cognitive decline.
-
Gene therapy combined with radiotherapy for brain tumors
This study is testing a new gene therapy combined with targeted radiation to see if it can safely help people with recurrent high-grade brain tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.